<DOC>
	<DOC>NCT02949024</DOC>
	<brief_summary>This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.</brief_summary>
	<brief_title>Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description>This is a Phase 1/2, multicenter, open-label study in subject with DME associated with diabetes mellitus. Subjects will be screened and if eligible, will be assigned to study arm at the Baseline Visit (Visit 1, Day 0). Following the Baseline Visit, subjects will participate in six month follow-up visits (Visit 2-7; Weeks 4-24) for safety and efficacy assessments and to determine whether additional therapy is needed based upon established criteria.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Men or women ≥ 18 years of age with type 1 or type 2 diabetes mellitus DME with central involvement in the study eye ETDRS BCVA letter score of 83 to 14, inclusive (Snellen equivalent of 20/25 to 20/500) in the study eye Intraocular pressure ≥ 22 mmHg or uncontrolled glaucoma (open angle or angle closure) in the study eye History of any previous ophthalmic surgeries in the study eye within 90 days of screening Subjects previously treated for DME cannot have been treated in the study eye with an intravitreal injection of antiVEGF or periocular corticosteroids within 90 days prior to screening (Previous TX arm only) Subjects previously treated for DME cannot have been treated in the study eye with intraocular corticosteroids within 6 months prior to screening (Previous TX arm only)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Diabetic retinopathy</keyword>
	<keyword>Microneedle</keyword>
	<keyword>Microinjection</keyword>
	<keyword>Triamcinolone</keyword>
	<keyword>Choroid</keyword>
	<keyword>Choroid Injection</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Suprachoroidal</keyword>
</DOC>